公开(公告)号：US20180292410A1

公开(公告)日：2018-10-11

申请号：US16008550

申请日：2018-06-14

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Farshid Dayyani ,  Friedemann Krause ,  Achim Escherich ,  Birgit Wehnl ,  Ying He ,  Vinzent Rolny ,  Sandra Rutz ,  Thomas Muley ,  Felix Herth ,  Julia Riedlinger

IPC: G01N33/574

Abstract: The present disclosure relates to a method of detecting a relapse of a lung adenocarcinoma in an individual based on marker human epididymis protein 4 (HE4) and optionally Cytokeratin-19 fragments (Cyfra21-1) as well as the use of a marker in the in vitro assessment of a relapse of a lung adenocarcinoma.

公开(公告)号：US20230358750A1

公开(公告)日：2023-11-09

申请号：US18352183

申请日：2023-07-13

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Anika Mang ,  Thomas Muley ,  Vinzent Rolny ,  Birgit Wehnl

IPC: G01N33/574

CPC classification number: G01N33/57423 ,  G01N2333/4742 ,  G01N2333/4725 ,  G01N2333/70596

Abstract: The present invention relates to an in vitro method for assessing the risk of non-small cell lung carcinoma (NSCLC) disease progression for a subject classified to have stable disease under an ongoing NSCLC treatment regime. The method involves determining the level of CYFRA 21-1 and/or the level of CA 125 in a sample obtained from the subject; and comparing (i) the determined level of CYFRA 21-1 to a CYFRA 21-1 cut-off level, (ii) the determined level of CA 125 to a CA 125 cut-off level, or (iii) a score taking into account the determined level of CYFRA 21-1 and/or the determined level of CA 125 to a cut-off score. The method of the invention further allows for assessing whether the subject responds to the ongoing treatment and/or whether the treatment regime should be maintained or modified. The invention also provides for corresponding uses, computer-implemented methods and computer program products.

公开(公告)号：US20180231557A1

公开(公告)日：2018-08-16

申请号：US15952731

申请日：2018-04-13

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Friedemann Krause ,  Vinzent Rolny ,  Farshid Dayyani ,  Achim Escherich ,  Birgit Wehnl ,  Ying He ,  Julia Riedlinger ,  Felix Herth ,  Thomas Muley

IPC: G01N33/574

CPC classification number: G01N33/57423 ,  G01N33/57484 ,  G01N2333/4742 ,  G01N2333/70596

Abstract: The present disclosure relates to a method of identifying an individual having non-small cell lung carcinoma as to be treated by chemotherapy based on marker molecules cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as well as the use of the marker molecules for the identification of an individual to be treated by chemotherapy.